7122 Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results
2009 ◽
Vol 7
(2)
◽
pp. 429-430
◽
Keyword(s):
Phase Ii
◽